COVID-19 pandemic in Sikkim | |
---|---|
Disease | COVID-19 |
Virus strain | SARS-CoV-2 |
Location | Sikkim, India |
First outbreak | Wuhan, Hubei, China |
Arrival date | 23 May 2020 (4 years, 1 week and 4 days) |
Confirmed cases | 13,132 (23 May 2021) |
Active cases | 3,527 |
Recovered | 9,381 (23 May 2021) |
Deaths | 224 |
Fatality rate | 1.71% |
Territories | All 4 districts |
Government website | |
www |
The first case of the COVID-19 pandemic in India was reported on 30 January 2020, originating from China. Slowly, the pandemic spread to various states and union territories including the state of Sikkim.
Below is the timeline of the cases of Sikkim:
18 March 2020 | Closure of all Educational Institutions. |
---|---|
21 May 2020 | Inaugurated Viral Research and Diagnostic Laboratories at STNM Hospital[1] |
23 May 2020 | First case confirmed in the state |
25 June 2020 | More than 10000 samples had been tested[2] |
11 July 2020 | Starts first Rapid antigen test[3] |
26 July 2020 | First death confirmed in the state[4] and Lockdown extend till 1 August[5] |
10 August 2020 | Total recovery crossed 500 |
14 August 2020 | Total confirmed cases crossed 1000[6] |
23 November 2020 | Total death 100 in the state[7] |
17 May 2021 | Started complete lockdown in Sikkim.[8] |
Samples tested | 110,183 |
---|---|
Positive | 13,132 |
Positive % | 11.92% |
Tests per million people [note 1] | 165,938 |
As of 23 May 2021 |
On January 1, 2021, the Drug Controller General of India, approved the emergency or conditional use of AstraZeneca's COVID-19 vaccine AZD1222 (marketed as Covishield).[42] Covishield is developed by the University of Oxford and its spin-out company, Vaccitech.[43] It's a viral vector vaccine based on replication-deficient Adenovirus that causes cold in Chimpanzees. It can be stored, transported and handled at normal refrigerated conditions (two-eight degrees Celsius/ 36-46 degrees Fahrenheit). It has a shelf-life of at least six months.
On 12 January 2021 first batches of Covishield vaccine was despatched from the Serum Institute of India.[44]
On January 2, 2021, BBV152 (marketed as Covaxin), first indigenous vaccine, developed by Bharat Biotech in association with the Indian Council of Medical Research and National Institute of Virology received approval from the Drug Controller General of India for its emergency or conditional usage.[45]
On 14 January 2021 first batches of Covaxin vaccine was despatched from the Bharat Biotech, albeit it was still in the third phase of testing.[46]
On 19 May 2021, Dr Reddy's Labs received Emergency Use Authorisation for anti-COVID drug 2-DG.[47] On 21 February, 2022, Drugs Controller General of India granted approval to Biological E's COVID-19 vaccine Corbevax, that can be used for children between 12 and 18 years of age.[48][49]
On 21 October 2021, India completed administering of one billion Covid vaccines in the country.[50]
On 8 January 2022, India crossed 1.5 billion Covid vaccines milestone in the country.[51]
On 19 February 2022, India crossed 1.75 billion Covid vaccines milestone in the country.[52]
| |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||||
Topics |
| ||||||||||||
Incidents |
| ||||||||||||
Locations |
| ||||||||||||
Legal framework |
| ||||||||||||
Agencies and institutes |
| ||||||||||||
Officials |
| ||||||||||||